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The establishment of antimeningococcic serum as a  specific  thera- 
peutic  agent  for  epidemic  or  meningococcus meningitis  antedated 
Dopter's  1 discovery of  the  duality  of  meningococci.  Previous  to 
Dopter's  studies the effort to produce a  so  called  polyvalent  anti- 
meningococcic serum  was  wholly  empirical.  Several  or  many  dif- 
ferent  strains  of  meningococcus were  employed for  inoculation  on 
the  supposition  that  such  biological  variations  as  occurred in  the 
species would be thus covered.  The discovery by Dopter of the para- 
meningococcus necessitated a change of procedure.  The strains  used 
for  inoculation  of  horses  were  now  chosen  according  to  whether 
they conformed serologically to the so called normal or regular menin- 
gococcus  or  the  parameningococcus.  Wollstein,  ~ who  studied  two 
of Dopter's cultures as well as a  considerable number of strains  iso- 
lated  in  the  United  States,  confirmed not  only the  serological dis- 
tinctions between normal and parameningococci, but made the im- 
portant  observation  that  between these two  extreme types a  num- 
ber of intermediate varieties were intercalated.  These intermediates 
inclined either  toward  the normal or  the para  organisms  but  were 
distinguishable serologically from both. 
The studies of the meningococcus stimulated by the appearance of 
epidemic meningitis in the armies of all the belligerent powers have 
served to confirm and in some degree to  extend the observations of 
Dopter and of Wollstein.  The present point of view is represented 
x  Dopter,  C., Compt. rend. Soc. biol., 1909, lxvii, 74. 
Wollstein, M., J. Exp. Med., 1914, xx, 201. 
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by the  classifications  of  Gordon  3 and  of Nicolle and  his  associates. 4 
Briefly stated they distinguish  also two main  types of meningococci 
designated  either  Types I  and  II  or A  and  B.  Gordon  also  recog- 
nizes Subtypes III and IV, one affiliating with Type II and the other 
with Type I, and Nicolle equally distinguishes two such  types, C  and 
D, which show similar  affiliations. 
The  serological subdivision of the meningococcus into varieties  or 
types has  undoubtedly marked  a  forward  step in  our knowledge  of 
the  causation  and  specific  treatment  of  epidemic  meningitis.  It 
may,  however,  perhaps  be  regarded  as  of questionable  value  to  set 
up too many minor  varieties  or types.  The  conditions  are not dis- 
similar  to  those  existing  among  the bacilli  of dysentery with which 
we have long been familiar.  In both instances the bacterial groups-- 
meningococci  and  dysentery  bacilli--seem  still  to  be  in  a  state  of 
specific flux.  In  the  case of meningococcus this  fact is made  espe- 
cially apparent by the study of carrier strains which show even greater 
serological fluctuation than do the strains obtained from the inflamed 
meninges. 5 
However, the  present  chief  interest  centers  around  the  establish- 
ment  of a  test of  therapeutic  efficiency in antimeningococcic  serum. 
It  does not  yet appear  feasible to  treat  epidemic meningitis  on  the 
basis of monovalent sera adapted in every instance to the particular 
type or variety of meningococcus  inducing  the infection.  Nor  does 
it  seem  necessary  to  attempt  this.  There  are  no  insuperable  diffi- 
culties in the way of preparing  an adequate polyvalent antimeningo- 
coccic serum in which not only the two main kinds of antibodies are 
sufficiently  represented  but  also  the  main  subvarieties  or  types  as 
well  Meningococci do not exhibit such strict serological specificity 
as we have become familiar with in regard  to  the  types of pneumo- 
cocci.  6  On  the  contrary,  there  is  much  overlapping  of  antibody 
3 Gordon, M. H., Great Britain National Health Insurance, Med. Research Com., 
Special Rep. Series, No. 3, 1917, 10. 
4 Nicolle, M., Debains, E., and Jouan, C., Ann. Inst. Pasteur, 1918, xxxii, 150. 
Eastwood, A., Rep. Local Gov. Bd. Pub. Health and  Med. Subjects,  1917, N.S. 
cxiv, 1.  Griffith, F.,  ibid.,  52.  Scott, W. M.,  ibid.,  111.  (See  also J.  Hyg., 
1918, xvii, 63,  124, 191.)  Gordon,  M. H., J. Hyg., 1918, xvii, 290. 
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reactions,  a  fact  which  affects  undoubtedly  the  wide  therapeutic 
applicability of the antimeningococcic serum. 
In spite of this overlapping it is imperative that a standard should 
be established which will afford a measure of the therapeutic efficacy 
of given  samples  of  the  serum.  An  efficient sample  of  the  serum 
should contain definite amounts of antibodies for the principal va- 
rieties  and  the  main  subvarieties  or  types  of  the  meningococcus. 
There will be no disagreement as to the two main types, while differ- 
ences of opinion may arise as to  the main subvarieties.  As regards 
the latter it will be safe to follow Gordon's  classification which ap- 
pears  to  express  the  essential  fact.  Accordingly  the  polyvalent 
antimeningococcic  serum  should  be  prepared  with  at  least  four 
properly chosen  cultures  of  the  meningococcus.  This  is  the  point 
of view arrived at  by  the New York State Department of Health, 
which has  adopted and is enforcing in the State a standard based on 
agglutination titerJ 
In choosing a  standard of value for the antimeningococcic serum 
certain questions  at  once arise.  The  first relates  to  the particular 
antibody on which therapeutic activity depends.  The point at issue 
with an antibacterial serum, as represented by the antimeningococcic 
serum, is far  more  complex  than  with  the  ordinary antitoxic  sera. 
According  to  present  beliefs  the  antimeningococcic serum  acts  (a) 
by increasing phagocytosis of the meningococcus,  8 (b)  by neutraliz- 
ing  endotoxin, 9 (c)  by  injuring  directly  the  meningococci and  im- 
pairing  their  power  of propagation? °  It  remains,  therefore,  to be 
determined whether any  one  criterion will  suffice as  a  measure of 
these several forms  of  activity. 
The methods employed to  effect the standardization of the serum 
have from time to  time undergone change.  Thus  there have been 
employed successively (a)  opsonin  content,  n  (b)  complement-fixing 
Off. Bull., New York State Dept. Health, 1918, iii, No. 5. 
8Jochmann,  Deutsch. reed. Woch., 1911, xxxvii, 1733.  Flexner, S.,  J. Exp. 
Med., 1907, ix, 168.  Flexner, S., and Amoss, H. L., J. Exp. Med., 1916, xxiii, 683. 
9 Flexner, S., J. Exp. Med.,  1907, ix, 168. 
10 Flexner, J. Exp. Med.,  1907, ix, 105.  Flexner, S., and Jobling, J.  W.,  J. 
Exp. Med., 1908, x, 141. 
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titery  (c)  agglutinin  content)  3  (d)  antiendotoxic  value)  4  and (e) 
protective power.  15 
The discrimination of parameningococcus from the regular meningo- 
coccus  has  automatically  rendered  the  opsonic  and  complement- 
binding  methods obsolete, since they do not suffice for the  separate 
determination  of the discrete antibodies.  In practice,  the discussion 
of standards has narrowed itself down to the relative merits of agglu- 
tinins  or protective power as a  measure  of value. 
It  is  desirable  to  state  here  that  agglutination  is  the  method  of 
choice for standardization,  since it alone gives clear distinctions  be- 
tween the types and varieties of meningococci.  Its employment has 
been questioned on the ground that as the therapeutic  action of ~he 
serum  is  probably not  a  function  of  the  agglutinin,  antibody  may 
not be a  measure  of therapeutic  efficacy.  An effort is being made, 
therefore,  to  substitute for the  agglutinin  content  of the  serum  the 
protective power. 
In endeavoring  to set up a  standard  of protection,  account must, 
in  the first instance,  be taken  of the  small  and  variable pathogenic 
action  of  the  meningococci.  This  fact  has  indeed  been  generally 
recognized  by investigators.  While  certain  small  animals,  such  as 
young guinea pigs weighing about 100 gm. 1. and mice, will often suc- 
cumb to intraperitoneal  inoculations of moderate doses of cultures of 
meningococci,  yet their  reaction is variable, and fluctuation  in viru- 
lence of the cultures is common. 
EXPERIMENTAL. 
Recently,  therefore,  Hitchens  and  Robinson 15  have  proposed  a  method  of 
standardization  of the antimeningococcic serum based on its protective  power. 
Because of the intrinsic importance of the subject  for our military organizations 
and our civil communities, we have submitted the method to a critical examination. 
12 Krumbein and Schatiloff, P.,  Deutsch.  reed. Woch.,  1908, xxiv, 1002. 
13 Amoss, H. L., and Wollstein, M., J. Exp. Med.,  1916, xxiii, 403.  Amoss, 
H. L., J. Am. Med. Assn.,  1917, lxix, 1137. 
la Flexner, J.  Exp.  Med.,  1907, ix,  168.  Dopter,  C., Compt. rend.  Soc.  biol., 
1909, Ixvi, 772.  Kraus,  R.,  and  Doerr,  R.,  Wien.  klin.  Woch.,  1908, xxi, 12. 
Gordon, M. H., Brit. Med. J., 1918, i, 110. 
15 Hitchens,  A. P.,  and Robinson, G. H., J. Immunol.,  1916, i, 345. 
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Hitchens and  Robinson give in  their  paper  what  we regard as illustrative 
protocols of their  experiments, from which they conclude that the "protection 
test  parallels the  extent  of immunization more nearly  than agglutination or 
complement fixation tests."  They also state that "there seems to be a consider- 
able degree of specificity in the test."  A close study of their protocols fails, we 
believe, to carry conviction that, even in their hands, the test is either delicate 
or decisive.  Unless  it is both delicate and decisive, the object which they seek, 
namely that "if the amount of serum necessary to protect against one M. L. D. 
of culture is considered  as a unit, a rational and uniform method of standardizing 
antimeningococcus serum can be obtained,"  and  "a dosage similar to that of 
antitoxic serum would be possible by such a  method of standardization" is not 
attained. 
In carrying out our experiments we have followed closely the con- 
ditions  laid  down  by  Hitchens  and  lkobinson.  Thus  a  16  hour 
growth of the meningococcus chosen was suspended in 1 cc. of dilute 
guinea pig  serum  and  injected immediately in  the  indicated doses 
into  the  peritoneal cavity of white mice.  In  testing the  action of 
samples of the antimeningococcic serum, 0.5  cc.  was injected intra- 
peritoneally 2 hours before the suspension of the culture was inocu- 
lated also  intraperitoneally.  Finally, in  instances in which  several 
cultures of a  given meningococcus were made, they were all washed 
off with the dilute guinea pig serum and pooled before being used for 
inoculation.  The volumes of serum and of bacterial suspension em- 
ployed have always  been  0.5  cc.  each. 
Series I.  Regular Menlngococcus. 
A  regular meningococcus having a suitable degree of virulence was 
selected.  The suspension was prepared in the manner indicated and 
injected immediately into the peritoneal cavity (Table I).  As Table 
I  shows, all but one of the injected mice died; but the order of their 
death did not conform to the dosage of the culture.  When death took 
place within 24 hours the peritoneal cavity and heart's blood yielded 
many or  innumerable  colonies  of  meningococcus; when  death  was 
delayed  the  number  of  colonies  grown  from the heart's  blood  was 
often few. 
The next  experiment was made with normal  serum  as  a  control 
for the antimeningococcic serum, and in duplicate in order to cover in 
a measure the variable response of the mice to the inoculation (Table 784  STANDARDIZATION  OF  ANTIMENINGOCOCCIC  SERUM 
TABLE  I. 
Virulence Test of Regular Meningococcus 4. 
Weight of mice.  Dose of suspension.  Result. 
gm, 
17 
15.5 
15 
14 
14 
0.5 
0.25 
0.12 
0.06 
0.03 
D.* 13 hrs. 
"  43  " 
"  17  " 
S.R. 
D.  9 hrs. 
* In the tables D. indicates died, S.R., sick and recovered, R., recovered. 
II).  The protocol brings out the facts (1) that the reaction of the mice 
to  the inoculation is irregular, and  (2)  that normal horse serum ex- 
hibits  no  protective  power  against  the  meningococcus.  Meningo- 
cocci in  large  numbers were  cultivated  from  the peritoneal  cavity 
and heart's blood of the mice dying within 24 hours. 
TABLE  II. 
Normal Horse Serum +  Regular Meningococcus 4. 
Weight of mice. 
Lot A.  Lot B. 
gm.  gm. 
16  16 
16  17 
15  15 
14  15 
13  14 
Dose of serum.  Dose of suSpen- 
sion. 
cc.  co. 
0.5  0.5 
0.5  0.25 
0.5  0.12 
0.5  0.06 
0.5  0.03 
Result. 
Lot A.  Lot B. 
D. 14 hrs.  D. 9 hrs. 
"  13  "  S.R. 
"  9  "  D. 57 hrs. 
"  37  "  R. 
"  9  "  D. 85 hrs. 
Two  experiments  were  made  with  polyvalent  antimeningococcic 
serum of high  titer  according to  the  standard  based  on  agglutinin 
content (Tables III and IV).  The serum also proved highly effective 
in  the treatment of cases of epidemic meningitis.  While Table III 
might be interpreted as giving evidence of protection,  Table IV  in- 
dicates  an  irregularity merely in  the  reaction  of the mice,  which 
cannot  depend  on  protection.  All  the  mice  of Lot  A  which  died 
yielded innumerable colonies  of  meningococcus from  the peritoneal 
cavity and heart's blood. HAROLD  L.  AMOSS  AND  PENELOPE  MARSH 
TABLE  III. 
Antimeningococcic  Serum  +  Regular Meningococcus  4. 
78.5 
Weight of mice.  Dose of serum.  Dose of suspension.  Result. 
gm. 
18 
17.5 
16.5 
17 
17 
CC. 
0.5 
0.5 
0.5 
0.5 
0.5 
CC. 
0.5 
0.25 
0.12 
0.06 
0.03 
D. 15 hrs. 
"  15  " 
S.R. 
*c 
D. 9  hrs. 
TABLE  IV. 
Antimeningococcic  Serum  +  Regular  Meningococcus  4. 
Weight of mice.  Result. 
Lot A.  Lot B. 
gra.  gm. 
15  17 
16  18 
16  15 
14  15 
12  12 
Dose of serum. 
co, 
0.5 
0.5 
0.5 
0.5 
0.5 
Dose  of suspen- 
sion. 
CO. 
0.5 
0.25 
0.12 
0.06 
0.03 
Lot A.  Lot B. 
D. 29½ hrs.  S.R. 
"  21  "  " 
"  24  "  D. 24 hrs. 
"  29  "  S.R. 
S.R.  " 
The next tests were made with a parameningococcus and the same 
samples of normal and antimeningococcic horse serum. 
Series II.  Parameningococcus. 
The  chief point  which  the  experiment  brings  out is the striking 
irregularity of the protection tests in this instance (Tables V to VII). 
TABLE  V. 
Control, Parameningococcus G. 
Weight of mice.  Dose of suspension.  Result. 
gm, 
20 
16 
14 
14 
15 
CC. 
0.5 
0.25 
0.12 
0.06 
0.03 
D. 27½ hrs. 
"  25½  " 
"  35  " 
"  24  " 
"  3½  "* 
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TABLE  VI. 
Normal Horse Serum  +  Parameningococcus  G. 
Weight of mice.  Dose of serum.  Dose of suspension.  Result. 
ggg. 
16 
15 
15 
15 
GG. 
0.5 
0.5 
0.5 
0.5 
CC. 
0.5 
0.25 
0.12 
0.06 
D. 16 hrs. 
S.R. 
D. 29½ hrs. 
"  16  " 
TABLE  VII. 
Antimeningococcic  Serum q- Parameningococcus  G. 
Weight of mice.  [  Result. 
Lot A.  Lot B. 
gm.  gr~. 
17  16 
16  15 
16  16 
15  14 
14  14 
Dose of serum. 
CC. 
0.5 
0.5 
0.5 
05 
0.5 
Dose of 
suspension. 
CC, 
0.5 
0.25 
0.12 
0.06 
0.03 
Lot A. 
D. 23 hrs. 
S.R. 
D. 6½ hrs. 
S.R.  ] 
D.  17 hrs.  ! 
Lot B. 
S.R. 
D.  10½ hrs. 
S.R. 
Series III.  Intermediate Meningococcus. 
The  next  test  was  carried  out  with  an  intermediate  or  irregular 
meningococcus tending slightly toward the regular (Tables VIII and 
IX).  According  to  the  agglutinin  standard  the  polyvalent  serum 
employed in this experiment was efficient; according to the protection 
test it is irregular in action and of practically no potency. 
TABLE  VIII. 
Control, Intermediate Meningococcus  30. 
Weight of mice. 
gm. 
15 
14 
14 
14 
13 
Dose of suspension. 
CC. 
0.5 
0.25 
0.12 
0.06 
0.03 
Result. 
D.  10½ hrs. 
"  10½  " 
S.R. 
D. 34 hrs. 
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TABLE  IX. 
Antimeningococdc  Serum  +  Intermediate Meningococcus  30. 
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Weight of mice. 
Lot A.  Lot B. 
g~.  g~. 
15  14 
13  13 
14  12 
13  13 
12  12 
Dose of serum. 
0.5 
0.5 
0.5 
0.5 
0.5 
Dose of 
suspension. 
CO. 
0.5 
0.25 
0.12 
0.06 
0.03 
Result. 
Lot A.  Lot B. 
D.  8 hrs.  D. 10 hrs. 
"  8  "  "  16  " 
"  10  "  "  27½" 
"  8  "  "  16  " 
"  29  "  S.R. 
The  final  tests were carried  out with  two samples of monovalent 
antimeningococcic  serum prepared  in  the  horse,  one for the normal 
or  regular  and  the  other  for  the  parameningococcus.  The  horses 
yielding the two samples of serum had been under immunization  for 
12 and 9 weeks respectively.  The agglutination  titers of the sera at 
the  time  the  protection  tests  were  made  was  +  to  ++  at  1:500 
dilution.  According  to  the  standard  followed  at  The  Rockefeller 
Institute  the  horses were  not  yet  ready  to  yield  therapeutic  sera. 
The  object was to ascertain whether  they would show any evidence 
of protective power. 
Series IV.  Monovalent Sera. 
In Tables X  and XI Lots 1 and 4 refer to the number of the regular 
culture  of meningococcus used for inoculation.  According to Table 
XI  the monovalent  serum  would have  to be regarded  as  devoid of 
antibodies, which is obviously, in view of the agglutination  titer,  not 
the  case. 
Perhaps  it  would  have  been  well  to  carry  the  suspensions  to  a 
greater  dilution;  namely,  to doses of 0.06  and  0.03  cc.  Since  these 
tests  were performed  during  the  period  last  spring  of  acute  mouse 
shortage,  the smaller doses were omitted, especially as in the control 
tests  the  mice  receiving  0.06  cc.  both  survived.  The  fact  that  of 
those given the monovalent  serum  one survived and  the other  died 
merely emphasizes  the irregularity  of this  test. 788  STANDARDIZATION  OF ANTIMENINGOCOCCIC  SERUM 
Control,  Re, 
Weight of mice. 
LOt  1.  ]  Lot 4. 
gm.  gln. 
15  15 
15  15 
15  15 
14  14 
TABLE  X. 
ular Meningococci  I  and 4. 
Dose of suspension. 
0.5 
0.25 
0.12 
0.06 
Lot 1. 
D. 30½ hrs. 
"  28  " 
S.R. 
Re~ 
Lot 4. 
D. 28 hrs. 
"  36  " 
"  30  " 
S.R. 
TABLE  XI. 
Regular Monovalent Serum  +  Regular Meningococci i  and 4. 
Weight of mice. 
Lotl.  Lot4. 
gm.  gm. 
15  17 
13  15 
13  14 
Dose of serum. 
CC. 
0.5 
0.5 
0.5 
Dose of suspen- 
sion. 
cc. 
0.5 
0.25 
0.12 
Result. 
Lot 1.  LOt 4. 
D. 17½ hrs.  D. 11  hrs. 
"  18  "  "  15½  " 
S.R.  "  13  " 
Tests  with  monovalent  para  serum  and  parameningococci  were 
also  carried  out.  Three  parameningococcus  cultures  were  employed 
(Tables  XII  and  XlII).  It  is  obvious  from  Tables  XlI  and  XlII 
that  the  tests  give  no  indication  of  protective  value  in  the  serum  in 
TABLE  XII. 
Control,  Parameningococci  60, 79, and 85. 
Weight of mice. 
Lot 60. 
gm. 
15 
15 
14 
14 
Lot  79. 
gin. 
15 
15 
14 
14 
Lot 85. 
gin. 
15 
15 
14 
14 
Dose of suspension. 
Lot 60. 
0.5  D. 9[ hrs. 
0.25  "  31  " 
0.12  "  31  " 
0.06  S.R. 
Result, 
Lot 79. 
D. 37 hrs. 
"  37  " 
"  31  " 
"  33  " 
Lot 85. 
D. 2~ hrs. 
"  33  " 
"  31  " 
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TABLE  XIII. 
Monovalent  Parameningococclc Serum  +  Parameningococd  60,  79,  and  gS. 
Weight of mice. 
Lot 60.  Lot 79.  Lot 85. 
gm.  gm.  gm. 
15  17  17 
15  15  15 
15  14  16 
13  13  13 
Dose of 
selalln. 
co. 
0.5 
0.5 
0.5 
0.5 
Dose of 
suspension. 
CO. 
0.5 
0.25 
0.12 
0.06 
Result. 
Lot 60.  Lot 79.  Lot 85. 
D. 11hrs.  D. 11hrs.  D. 19hrs. 
"  7  "  S.R.  "  11  " 
S.R.  D. 13hrs.  "  19  " 
"  "  21  "  "  20  " 
spite  of a  moderate content  of  agglutinin  and  doubtless  of  thera- 
peutic principles. 
The last two series of experiments were reversed so that the mono- 
valent sera were made to react with their opposite cultures--the regu- 
lar serum with para cultures and the para serum with regular cultures. 
Aside from what appeared  to  be an accidental survival,  all  the in- 
oculated mice succumbed. 
DISCUSSION. 
In carrying out the experiments described in this paper no attempt 
was made to restudy, in an intensive manner, the general subject of 
the  protective  power  of  the  antimeningococcic serum  on  animals. 
The purpose was merely to repeat the experiments of Hitchens and 
Robinson on which they base their argument for a protection standard 
for  the antimeningococcic serum. 
Our results failed wholly to confirm those of Hitchens and Robin- 
son  and  conform to  the  earlier  studies  in  indicating  that  infection 
tests carried out in laboratory animals with the meningococcus give 
extremely variable results, and that  this factor of variability enters 
into and affects unfavorably the protection tests. 
Investigators  are  generally  agreed  that  the  antimeningococcic 
serum possesses protective power against experimental meningococcic 
infection.  This power is shown either by the survival of the inocu- 
lated  and  serum-treated animal  or by reduction in  the  number  of 
meningococci and increase in intensity  of  the  phagocytosis within 
the  peritoneal  cavity.  But  not  only  are  these  reactions irregular 790  STANDARDIZATION OF ANTIM-ENINGOCOCCIC SERU~I 
in  their  occurrence  but  they  are  confined  within relatively narrow 
limits and may succeed only when  the minimum  lethal  dose  of  the 
culture inoculated is not exceeded.  Reactions of this  order  are  not 
well suited for purposes of standardization. 
CONCLUSIONS. 
Experiments  were made for the purpose of testing  the reaction  of 
protection against infection as a  measure of potency of antimeningo- 
coccic serum. 
The  results  of the  experiments  were extremely variable  and  bore 
no relation  to the quality of the sera as determined by the period of 
immunization  of the  horses from which  they were obtained,  or  the 
indications  of  efficiency  based  upon  their  employment  in  human 
cases of epidemic meningitis. 
The  results  also  failed  entirely  to  conform  to  the  agglutination 
titer of the sera tested and to be affected by the different type forms 
of the meningococci. 
We regard the protective power for laboratory animals of the anti- 
meningococcic  serum  as  an  unsuitable  index  of its  value in  human 
medicine  and  as inferior  to  the  agglutination  titer  as  a  standard  of 
potency. 